Final Results of a phase III trial of celecoxib (C) in addition to standard chemotherapy for advanced NSCLC with COX- 2 overexpression: CALGB 30801 (Alliance)
- Citation:
- Int J Radiat Oncol Biol Phys vol 98 (1) 220-1
- Meeting Instance:
- MSTO 2017
- Year:
- 2017
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2600
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10CA180821, U10CA180882
- Corr. Author:
- Authors:
- Martin J. Edelman Xiaofei Wang Lydia Hodgson Richard T. Cheney Maria Q. Baggstrom Thomas Sachdev Ajeet Gajra Erin Bertino Karen L. Reckamp Julian Molina Joan Schiller Kisha Mitchell-Richards Paula N. Friedman Jon Ritter Ginger Milne Olwen Hahn Thomas Stinchcombe Everett E. Vokes
- Networks:
- CA043, LAPS-IL036, LAPS-IL057, LAPS-MN026, LAPS-MO011, LAPS-NC010, MD015, NY175, OH008, VA002
- Study
- CALGB-30801
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: